It has been known for some time that laminins containing α1 and α2 chains, which are normally restricted to the mesangial matrix, accumulate in the glomerular basement membranes (GBM) of Alport mice, dogs, and humans. We show that laminins containing the α2 chain, but not those containing the α1 chain activates focal adhesion kinase (FAK) on glomerular podocytes in vitro and in vivo. CD151-null mice, which have weakened podocyte adhesion to the GBM rendering these mice more susceptible to biomechanical strain in the glomerulus, also show progressive accumulation of α2 laminins in the GBM, and podocyte FAK activation. Analysis of glomerular mRNA from both models demonstrates significant induction of MMP-9, MMP-10, MMP-12, MMPs linked to GBM destruction in Alport disease models, as well as the pro-inflammatory cytokine IL-6. SiRNA knockdown of FAK in cultured podocytes significantly reduced expression of MMP-9, MMP-10 and IL-6, but not MMP-12. Treatment of Alport mice with TAE226, a small molecule inhibitor of FAK activation, ameliorated fibrosis and glomerulosclerosis, significantly reduced proteinuria and blood urea nitrogen levels, and partially restored GBM ultrastructure. Glomerular expression of MMP-9, MMP-10 and MMP-12 mRNAs was significantly reduced in TAE226 treated animals. Collectively, this work identifies laminin α2-mediated FAK activation in podocytes as an important early event in Alport glomerular pathogenesis and suggests that FAK inhibitors, if safe formulations can be developed, might be employed as a novel therapeutic approach for treating Alport renal disease in its early stages.
References
[1]
Kruegel J, Rubel D, Gross O (2013) Alport syndrome—insights from basic and clinical research. Nat Rev Nephrol 9: 170–178. doi: 10.1038/nrneph.2012.259
[2]
Abrahamson DR, Isom K, Roach E, St John PL (2007) Laminin compensation in collagen alpha3(IV) knockout (Alport) glomeruli contributes to permeability defects. J Am Soc Nephrol 18: 2465–2472. doi: 10.1681/asn.2007030328
[3]
Gunwar S, Ballester F, Noelken ME, Sado Y, Hudson BG (1998) Glomerular basement membrane. Identification of a novel disulfide-cross-linked network of alpha3, alpha4, and alpha5 chains of type IV collagen and its implications for the pathogenesis of Alport syndrome. J Biol Chem 273: 8767–8775. doi: 10.1074/jbc.273.15.8767
[4]
Rao VH, Meehan DT, Delimont D, Nakajima M, Gratton MA, et al. (2006) Role for macrophage metalloelastase in glomerular basement membrane damage associated with Alport syndrome. Am J Pathol 169: 32–46. doi: 10.2353/ajpath.2006.050896
[5]
Zeisberg M, Khurana M, Rao VH, Cosgrove D, Rougier JP, et al. (2006) Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease. PLoS Med 3: e100. doi: 10.1371/journal.pmed.0030100
[6]
Sayers R, Kalluri R, Rodgers KD, Shield CF III, Meehan DT, et al. (1999) Role for transforming growth factor-α1 in Alport renal disease progression. Kidney Int 56: 1662–1673. doi: 10.1046/j.1523-1755.1999.00744.x
[7]
Koepke ML, Weber M, Schulze-Lohoff E, Beirowski B, Segerer S, et al. (2007) Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome. Nephrol Dial Transplant 22: 1062–1069. doi: 10.1093/ndt/gfl810
[8]
Cosgrove D, Rodgers K, Meehan D, Miller C, Bovard K, et al. (2000) Integrin alpha1beta1 and transforming growth factor-beta1 play distinct roles in Alport glomerular pathogenesis and serve as dual targets for metabolic therapy. Am J Pathol 157: 1649–1659. doi: 10.1016/s0002-9440(10)64802-x
[9]
Cosgrove D, Meehan DT, Delimont D, Pozzi A, Chen X, et al. (2008) Integrin α1β1 regulates matrix metalloproteinases via P38 mitogen-activated protein kinase in mesangial cells: Implications for Alport syndrome. Am J Pathol 172: 761–773. doi: 10.2353/ajpath.2008.070473
[10]
Kashtan CE, Kim Y, Lees GE, Thorner PS, Virtanen I, et al. (2001) Abnormal glomerular basement membrane laminins in murine, canine, and human Alport syndrome: aberrant laminin alpha2 deposition is species independent. J Am Soc Nephrol 12: 252–260.
[11]
Zallocchi M, Johnson B, Meehan DT, Delimont D, Rogers KD, et al. (2013) α1β1 integrin/Rac1-dependent mesangial invasion of glomerular capillaries in Alport syndrome. Am. J. Pathol. 183: 1269–80. doi: 10.1016/j.ajpath.2013.06.015
[12]
Zeng AA, Jia Y, Hahn NJ, Markwart SM, Rockwood KF, et al. (2006) Role of focal adhesion kinase and phosphatidylinositol 3′-kinase in integrin fibronectin receptor-mediated, matrix metalloproteinase-1-dependent invasion by metastatic prostate cancer cells. Cancer Res 66: 8091–8099. doi: 10.1158/0008-5472.can-05-4400
[13]
Cosgrove D, Meehan DT, Grunkemeyer JA, Kornak JM, Sayers R, et al. (1996) Collagen COL4A3 knockout: A mouse model for autosomal Alport syndrome. Genes Dev 10: 2981–2992. doi: 10.1101/gad.10.23.2981
[14]
Takeda Y, Kazarov AR, Butterfield CE, Hopkins BD, Benjamin LE, et al. (2007) Deletion of tetraspanin Cd151 results in decreased pathologic angiogenesis in vivo and in vitro. Blood 109: 1524–1532. doi: 10.1182/blood-2006-08-041970
[15]
Meehan DT, Delimont D, Cheung L, Zallocchi M, Sansom SC, et al. (2009) Biomechanical strain mediated maladaptive gene regulation as a contributing factor in Alport glomerular disease. Kidney Int 76: 968–976. doi: 10.1038/ki.2009.324
[16]
Abrahamson DR, Prettyman AC, Robert B, St John PL (2003) Laminin-1 reexpression in Alport mouse glomerular basement membranes. Kidney Int 63: 826–34. doi: 10.1046/j.1523-1755.2003.00800.x
[17]
Van Slambrouch S, Brijelmo C, De Wever O, Bruyneel E, Emami S, et al. (2007) Activation of the FAK-src molecular scaffolds and p130Cas-JNK signaling cascades by alpha1-integrins during colon cancer cell invasion. Int J Oncol 31: 1501–1508. doi: 10.3892/ijo.31.6.1501
[18]
Chen YJ, Wei YY, Chen HT, Fong YC, Hsu CJ, et al. (2009) Osteopontin increases migration and MMP-9 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells. J Cell Physiol 221: 98–108. doi: 10.1002/jcp.21835
[19]
Oh JH, Kim JH, Ahn HJ, Yoon JH, Yoo SC, et al. (2009) Syndecan-1 enhances the endometrial cancer invasion by modulating matrix metalloproteinase-9 expression through nuclear factor kappaB. Gynecol Oncol 114: 509–515. doi: 10.1016/j.ygyno.2009.05.027
Tseng WP, Su CM, Tang CH (2010) FAK activation is required for TNF-alpha-induced IL-6 production in myoblasts. J Cell Physiol 223: 389–396. doi: 10.1002/jcp.22047
[22]
Ma H, Togawa A, Soda K, Zhang J, Lee S, et al. (2010) Inhibition of podocyte FAK protects against proteinuria and foot process effacement. J AM Soc Nephrol 21: 1145–1156. doi: 10.1681/asn.2009090991
[23]
Cosgrove D, Meehan DT, Pozzi A, Chen X, Rodgers KD, et al. (2008) Integrin α1β1 regulates MMPs via p38 MAPkinase in mesangial cells: implications for Alport syndrome. Am. J. Pathol. 172: 761–773. doi: 10.2353/ajpath.2008.070473
[24]
Sampson NS, Ryan ST, Enke DA, Cosgrove D, Koteliansky V, et al. (2001) Identification of a role for alpha1 integrin in renal pathogenesis using global analysis of gene expression. J Biol Chem 276: 34182–34188. doi: 10.1074/jbc.m102859200
[25]
Dennis J, Meehan DT, Delimont D, Zallocchi M, Perry GA, et al. (2010) Collagen XIII mediates VLA-1 dependent monocyte transendothelial migration in renal fibrosis. Am J Pathol 177: 2527–2540. doi: 10.2353/ajpath.2010.100017
[26]
Li X, Hunter D, Morris J, Haskill JS, Earp HS (1998) A calcium-dependent tyrosine kinase splice variant in human monocytes. Activation by a two-stage process involving adherence and a subsequent intracellular signal. J Biol Chem 273: 9361–9364. doi: 10.1074/jbc.273.16.9361
[27]
Horikoshi S, Ebihara I, Nakamura T, Koide H (1999) Abnormal distribution of mesangium-specific laminin in glomeruli of patients with idiopathic membranous nephropathy. Nephron 81: 284–288. doi: 10.1159/000045294
[28]
Fischer E, Mougenot B, Callard P, Ronco P, Rossert J (2000) Abnormal expression of glomerular basement membrane laminis in membranous glomerulonephritis. Nephrol Dial Transplant 15: 1959–1994. doi: 10.1093/ndt/15.12.1956
[29]
Andrews KL, Betsuyaku T, Rogers S, Shipley JM, Senior RM, et al. (2000) Gelatinase B. (MMP-9) is not essential in the normal kidney and does not influence the progression of renal disease in a mouse model of Alport syndrome. Am J Pathol 157: 303–311. doi: 10.1016/s0002-9440(10)64541-5
[30]
Baleato RM, Guthrie PL, Gublerr MC, Ashman LK, Roselli S (2008) Deletion of CD151 results in a strain-dependent glomerular disease due to severe alterations of the glomerular basement membrane. Am J Pathol 173: 927–37. doi: 10.2353/ajpath.2008.071149
[31]
Sanchez-Lopez R, Alexander CM, Behrendtsen O, Breathnach R, Werb Z (1993) Role of zinc-binding- and hemopexin domain-encoded sequences in the substrate specificity of collagenase and stromelysin-2 as revealed by chimeric proteins. J Biol Chem 268: 7238–7247.
[32]
Nagase H (2001) Substrate Specificity of MMPs. Cancer Drug Discovery and Development: Matrix Metalloproteinase Inhibitors in Cancer Therapy. Edited by Clendeninn JJ and Krzysztof A. Totowa, NJ, Humana Press Inc.,:39–66.
[33]
Beg AA, Ruben SM, Scheinman RI, Haskill S, Rosen CA, et al. (1992) I kappa B interacts with the nuclear localization sequences of the subunits of NF-kappa B: a mechanism for cytoplasmic retention. Genes Dev 6: 1899–1913. doi: 10.1101/gad.6.10.1899
[34]
Hansen K, Abrass CK (2003) Laminin-8/9 is synthesized by rat glomerular mesangial cells and is required for PDGF-induced mesangial cell migration. Kidney Int 64: 110–118. doi: 10.1046/j.1523-1755.2003.00039.x
